Roquefort Therapeutics (LON:ROQ) Stock Price Down 8.9% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ) dropped 8.9% during mid-day trading on Wednesday . The stock traded as low as GBX 2 ($0.03) and last traded at GBX 2.01 ($0.03). Approximately 1,972,329 shares changed hands during trading, a decline of 40% from the average daily volume of 3,297,688 shares. The stock had previously closed at GBX 2.20 ($0.03).

Roquefort Therapeutics Trading Down 2.8 %

The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The business has a 50 day moving average price of GBX 2.66 and a 200-day moving average price of GBX 3.55. The firm has a market capitalization of £2.66 million, a PE ratio of -1.73 and a beta of 0.05.

Insider Buying and Selling

In related news, insider Stephen Paul West acquired 400,000 shares of Roquefort Therapeutics stock in a transaction that occurred on Tuesday, February 4th. The stock was purchased at an average price of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($15,560.17). 60.40% of the stock is currently owned by corporate insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.